Characterizing Uncertainty and Variability in Physiologically Based Pharmacokinetic Models: State of the Science and Needs for Research and Implementation-Reference-Cited by-同舟云学术

Characterizing Uncertainty and Variability in Physiologically Based Pharmacokinetic Models: State of the Science and Needs for Research and Implementation

Published:2007-05-04 Issue:2 Volume:99 Page:395-402
ISSN:1096-6080
Container-title:Toxicological Sciences
language:en
Short-container-title:

Author:

Barton Hugh A.,Chiu Weihsueh A.,Woodrow Setzer R.,Andersen Melvin E.,Bailer A. John,Bois Frédéric Y.,DeWoskin Robert S.,Hays Sean,Johanson Gunnar,Jones Nancy,Loizou George,MacPhail Robert C.,Portier Christopher J.,Spendiff Martin,Tan Yu-Mei

Publisher

Oxford University Press (OUP)

Subject

Toxicology

Link

http://academic.oup.com/toxsci/article-pdf/99/2/395/10955729/kfm100.pdf

Reference40 articles.

1. Applying simulation modeling to problems in toxicology and risk assessment—A short perspective;Toxicol. Appl. Pharmacol.,1995

2. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride;Toxicol. Appl. Pharmacol.,1987

3. Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats;Toxicol. Sci.,2001

4. Methotrexate pharmacokinetics;J. Pharm. Sci.,1971

5. Optimal design for a study of butadiene toxicokinetics in humans;Toxicol. Sci.,1999

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analyzing parametric influences driving age-associated changes in absorption using a PBPK-GSA approach;European Journal of Pharmaceutical Sciences;2024-11

2. Enabling Transparent Toxicokinetic Modeling for Public Health Risk Assessment;2024-08-21

3. Construction of a physiologically based pharmacokinetic model of paclobutrazol and exposure estimation in the human body;Toxicology;2024-06

4. In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software;Biopharmaceutics & Drug Disposition;2023-04-21

5. Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data;Frontiers in Pharmacology;2023-03-23